Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:24:16 EDT Wed 12 Aug 2026
Enter Symbol
or Name
USA
CA



Q:GILD - GILEAD SCIENCES INC - https://www.gilead.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.1135.37·136.640.1135.87+0.100.15,683.8769,63558,590133.99  137.115  133.295157.27  108.460117:01:07Aug 0415 min RT 2¢

Recent Trades - Last 10 of 58590
Time ETExPriceChangeVolume
17:01:07Q136.4030.63310
16:54:55Q135.870.10277
16:47:14Q135.870.10124,573
16:45:04Q135.85750.08751
16:26:54Q135.38-0.393
16:20:01Q135.6304-0.13963
16:15:09Q135.870.101
16:15:09Q135.870.101
16:15:00Q135.870.101
16:15:00Q135.870.101

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-04 13:01U:GILDNews ReleaseCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
2026-07-24 06:26U:GILDNews ReleaseCHMP Recommends Gilead's Trodelvy(TM) Plus Keytruda(TM) in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
2026-07-21 16:05U:GILDNews ReleaseGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-21 10:00U:GILDNews ReleaseInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
2026-07-21 10:00U:GILDNews ReleaseGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
2026-06-24 16:29U:GILDNews ReleaseU.S. FDA Approves Trodelvy(TM) for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
2026-06-24 08:30U:GILDNews ReleaseNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
2026-06-23 07:45U:GILDNews ReleaseEuropean Commission Approves Trodelvy(TM) as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
2026-06-15 16:34U:GILDNews ReleaseU.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
2026-06-12 08:30U:GILDNews ReleaseGilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
2026-06-11 08:30U:GILDNews ReleaseNational AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
2026-06-08 16:35U:GILDNews ReleaseGilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
2026-06-08 16:30U:GILDNews ReleaseMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
2026-06-05 03:00U:GILDNews ReleaseGilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
2026-06-04 16:15U:GILDNews ReleaseGilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
2026-06-02 08:30U:GILDNews ReleaseGilead's Livdelzi(TM) (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
2026-05-27 02:00U:GILDNews ReleasePhase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1-1.67*ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
2026-05-22 14:00U:GILDNews ReleaseFDA Grants Accelerated Approval to Gilead's Hepcludex(TM) (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
2026-05-22 07:47U:GILDNews ReleaseGilead Receives CHMP Positive Opinion for Trodelvy(TM) in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
2026-05-21 17:00U:GILDNews ReleaseNew ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology